Big Pharma's playbook was built for vast portfolios, not lean pipelines. Inovia's Biotech Strategy replaces it with rapid, iterative learning, non-linear development and real-world evidence, so you reach the decisions that matter faster and on a fraction of the runway.
Based on our market research with 22 biotechs
The traditional waterfall model's rigid, sequential phases lack early feedback, delaying critical insights. Late-stage failures devastate a lean biotech's limited runway, unlike agile, iterative approaches that de-risk programmes early.
Manual, outdated methods for data analysis, like delayed real-world evidence, waste months and capital. Nimble biotechs need rapid, RWE-driven insights to pivot quickly and stay ahead of evolving science.
The traditional playbook generates evidence without ruthless prioritisation or continuous updates. Lean biotechs need a dynamic integrated evidence plan to prioritise high-impact data and adapt to shifting markets.
Big Pharma's resource-heavy processes, designed for vast portfolios, burden small biotechs with costly, inflexible strategies. Nimble biotechs need lean, non-linear models to accelerate focused assets efficiently.
Six ways we replace the linear playbook with agile, evidence-led strategy, so every study earns its place and your runway goes further.
Leverage cutting-edge real-world evidence platforms to gain critical insights in days, not months, powering swift, data-driven decisions that extend your runway.
Create a streamlined integrated evidence plan (IEP) that prioritises high-impact studies, so every study earns its place against your regulatory, investor or payer goals.
Integrate RWE early to understand patient needs and refine trial design, catching issues upfront to avoid costly missteps and boost programme credibility.
Replace rigid development with agile, evidence-driven sprints, so you adapt quickly to new science, market shifts or regulatory change.
Treat each evidence-generation need as a strategic investment with its own proposition, and run only the activities that bring the highest return.
Collaborate with Inovia's forward-thinking team, blending clinical development expertise and innovative technology to guide your biotech to its milestones with precision.
Our early-stage playbook: the First-100-Days Playbook, briefs and articles on standing up evidence strategy in the right order. Free, no pitch.
Inovia's seasoned drug development team excels at guiding assets through approval, while pioneering strategies tailored to each biotech's unique pipeline for agility and success.
Leverage our proprietary platforms, InoviaIEP, InovaLandscape, RWE360 and InovaMine, to deliver regulatory-grade outcomes in minutes, not months, and outpace every CRO.
Trusted by global biotechs, our track record spans multiple development stages and dozens of clinical programmes, delivering measurable results that accelerate milestones.
Every study, endpoint and decision in a strong strategy should trace back to one graded target profile. This is the template we use to build it, so your plan is designed around the label you actually want.
✓ Grade every attribute from minimal acceptable to best-in-class
✓ Efficacy, safety, dosing, comparator, regulatory and differentiation, with traceable attribute IDs
✓ Built to align to your strategy, so every study earns its place
Inovia anticipates the unexpected, proactively crafting strategic scenarios to navigate a dynamic biotech landscape. Our RWE360 platform consistently outperforms manual studies, delivering deeper, faster real-world evidence insights tailored to your needs.
The Inovia Biotech Strategy is a framework designed to streamline biotech development. It combines real-world evidence, advanced technology platforms and expert insight to help biotech companies overcome the inefficiencies of traditional pharma, accelerate development and achieve better outcomes.
The Biotech Strategy accelerates success by delivering rapid insights through technology, maximising ROI with lean evidence plans, reducing risk through early RWE integration, and keeping you agile with dynamic, competitive market narratives.
The Biotech Strategy supports both ongoing projects and new initiatives. Its agile, RWE-driven approach and lean evidence plans adapt to any stage, optimising existing programmes or launching new ones with efficiency and precision.
The Inovia Biotech Strategy breaks from traditional approaches by replacing rigid, linear development with agile, non-linear strategy. It leverages real-world evidence (RWE) and lean integrated evidence plans (IEPs) to deliver rapid insights, reduce risk and align every study with your strategic goals, keeping nimble biotechs efficient and adaptable.
Yes. Its lean integrated evidence plans (IEPs) and real-world evidence (RWE) generate high-impact data that strengthens investor confidence. By demonstrating clear milestones, reduced risk and a compelling value narrative, the Biotech Strategy showcases your biotech's potential to funders.
-1.png?width=1169&height=277&name=Inovia%20Logo%20Dark%20(1)-1.png)